Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment.

Khan MA, Walley JD, Witter SN, Imran A, Safdar N.

Health Policy Plan. 2002 Jun;17(2):178-86.

PMID:
12000778
2.

Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.

Vassall A, Bagdadi S, Bashour H, Zaher H, Maaren PV.

Int J Tuberc Lung Dis. 2002 Dec;6(12):1083-90.

PMID:
12546116
3.

Directly observed therapy for treating tuberculosis.

Karumbi J, Garner P.

Cochrane Database Syst Rev. 2015 May 29;(5):CD003343. doi: 10.1002/14651858.CD003343.pub4. Review.

4.

Patients' costs and cost-effectiveness of tuberculosis treatment in DOTS and non-DOTS facilities in Rio de Janeiro, Brazil.

Steffen R, Menzies D, Oxlade O, Pinto M, de Castro AZ, Monteiro P, Trajman A.

PLoS One. 2010 Nov 17;5(11):e14014. doi: 10.1371/journal.pone.0014014.

6.

A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis.

Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR.

Chest. 1997 Jul;112(1):63-70.

PMID:
9228359
8.

Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan.

Walley JD, Khan MA, Newell JN, Khan MH.

Lancet. 2001 Mar 3;357(9257):664-9.

PMID:
11247549
9.
10.

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.

11.

Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi.

Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F.

Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S29-37.

PMID:
12971652
12.

Cost-effectiveness of various tuberculosis control strategies in Thailand.

Hunchangsith P, Barendregt JJ, Vos T, Bertram M.

Value Health. 2012 Jan-Feb;15(1 Suppl):S50-5. doi: 10.1016/j.jval.2011.11.006.

13.

Cost-effectiveness of treating multidrug-resistant tuberculosis.

Resch SC, Salomon JA, Murray M, Weinstein MC.

PLoS Med. 2006 Jul;3(7):e241.

14.

Cost comparison of wirelessly vs. directly observed therapy for adherence confirmation in anti-tuberculosis treatment.

Au-Yeung KY, DiCarlo L.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1498-504. doi: 10.5588/ijtld.11.0868. Epub 2012 Sep 18.

PMID:
23006834
15.
16.

A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis.

Palmer CS, Miller B, Halpern MT, Geiter LJ.

J Public Health Manag Pract. 1998 May;4(3):1-13.

PMID:
10186738
17.

Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia.

Jacobs B, Clowes C, Wares F, Polivakho V, Lyagoshina T, Peremitin G, Banatvala N.

Int J Tuberc Lung Dis. 2002 May;6(5):396-405.

PMID:
12019915
18.

A randomized controlled study comparing community based with health facility based direct observation of treatment models on patients' satisfaction and TB treatment outcome in Nigeria.

Adewole OO, Oladele T, Osunkoya AH, Erhabor GE, Adewole TO, Adeola O, Obembe O, Ota MO.

Trans R Soc Trop Med Hyg. 2015 Dec;109(12):783-92. doi: 10.1093/trstmh/trv091.

PMID:
26626341
19.

Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis.

Getahun B, Wubie M, Dejenu G, Manyazewal T.

Infect Dis Poverty. 2016 Nov 1;5(1):93.

20.

[Tuberculosis in Asia].

[No authors listed]

Kekkaku. 2002 Oct;77(10):693-7. Japanese.

PMID:
12440145

Supplemental Content

Support Center